See more : Mini Diamonds (India) Limited (MINID.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Navidea Biopharmaceuticals, Inc. (NAVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Navidea Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sreeleathers Limited (SREEL.BO) Income Statement Analysis – Financial Results
- Dune Acquisition Corporation (DUNEU) Income Statement Analysis – Financial Results
- Kyungin Synthetic Co., Ltd. (012610.KS) Income Statement Analysis – Financial Results
- Osisko Green Acquisition Limited (GOGR.TO) Income Statement Analysis – Financial Results
- Heliad AG (A7A.DE) Income Statement Analysis – Financial Results
Navidea Biopharmaceuticals, Inc. (NAVB)
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.65K | 531.51K | 915.01K | 26.62K | 322.52K | 1.81M | 21.97M | 13.25M | 6.27M | 1.13M | 78.74K | 597.73K | 10.70M | 9.52M | 7.89M | 7.12M | 6.05M | 5.92M | 5.95M | 6.51M | 4.92M | 7.58M | 9.71M | 9.45M | 5.83M | 5.13M | 1.17M | 1.00M | 900.00K | 100.00K | 100.00K |
| Cost of Revenue | 184.95K | 198.83K | 1.05K | 6.67K | 96.64K | 3.65K | 2.30M | 1.75M | 1.59M | 332.82K | 0.00 | 0.00 | 3.21M | 3.13M | 3.01M | 3.18M | 2.63M | 2.38M | 2.34M | 3.12M | 2.35M | 4.39M | 4.63M | 3.95M | 1.40M | 1.58M | 676.77K | 500.00K | 100.00K | 5.90M | 100.00K |
| Gross Profit | -119.30K | 332.68K | 913.97K | 19.95K | 225.89K | 1.81M | 19.67M | 11.49M | 4.69M | 797.82K | 78.74K | 597.73K | 7.49M | 6.38M | 4.88M | 3.94M | 3.42M | 3.54M | 3.61M | 3.38M | 2.57M | 3.20M | 5.08M | 5.49M | 4.43M | 3.55M | 494.41K | 500.00K | 800.00K | -5.80M | 0.00 |
| Gross Profit Ratio | -181.71% | 62.59% | 99.89% | 74.95% | 70.04% | 99.80% | 89.54% | 86.76% | 74.72% | 70.56% | 100.00% | 100.00% | 70.03% | 67.07% | 61.83% | 55.30% | 56.50% | 59.86% | 60.61% | 52.00% | 52.22% | 42.17% | 52.31% | 58.13% | 75.93% | 69.27% | 42.21% | 50.00% | 88.89% | -5,800.00% | 0.00% |
| Research & Development | 5.97M | 5.14M | 4.93M | 5.34M | 4.22M | 4.51M | 8.88M | 12.79M | 16.78M | 23.71M | 16.89M | 15.15M | 9.22M | 4.97M | 4.51M | 2.87M | 3.80M | 4.03M | 2.45M | 1.89M | 2.32M | 344.68K | 472.73K | 1.31M | 12.96M | 19.66M | 16.08M | 7.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 7.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.96M | 7.45M | 6.69M | 6.28M | 7.70M | 11.17M | 13.01M | 17.26M | 15.54M | 15.53M | 11.18M | 9.55M | 4.58M | 3.24M | 3.41M | 2.84M | 3.08M | 3.16M | 3.15M | 3.10M | 3.27M | 2.32M | 2.96M | 8.21M | 10.55M | 11.16M | 7.75M | 3.60M | 12.00M | 2.30M | 2.90M |
| Other Expenses | 0.00 | -14.12K | -21.86K | -631.21K | 1.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 552.96K | 9.38M | 0.00 | 0.00 | 500.00K | 600.00K | 100.00K | 100.00K |
| Operating Expenses | 13.93M | 12.59M | 11.63M | 10.98M | 11.07M | 15.68M | 21.90M | 30.05M | 32.32M | 39.24M | 28.07M | 24.70M | 13.80M | 8.21M | 7.92M | 41.23M | 6.88M | 7.19M | 5.61M | 5.00M | 5.59M | 2.67M | 3.43M | 10.07M | 32.90M | 30.82M | 23.84M | 11.90M | 12.60M | 2.40M | 3.00M |
| Cost & Expenses | 14.12M | 12.59M | 11.63M | 10.99M | 11.17M | 15.69M | 24.19M | 31.80M | 33.91M | 39.57M | 28.07M | 24.70M | 17.01M | 11.34M | 10.93M | 44.42M | 9.51M | 9.56M | 7.95M | 8.12M | 7.94M | 7.05M | 8.06M | 14.03M | 34.30M | 32.39M | 24.51M | 12.40M | 12.70M | 8.30M | 3.10M |
| Interest Income | 0.00 | 6.00K | 11.34K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 16.10K | 18.84K | 25.04K | 25.76K | 8.80K | 18.75K | 60.86K | 70.98K | 225.47K | 226.66K | 28.87K | 9.42K | 74.26K | 127.66K | 205.96K | 0.00 | 598.83K | 0.00 | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.10M | 6.36K | 0.00 | 25.29K | 30.80K | 168.97K | 4.87K | 1.27M | 3.71M | 2.78M | 1.17M | 13.33K | 554.99K | 1.53M | 1.74M | 2.28M | 1.50M | 1.35M | 334.20K | 186.91K | 31.95K | 11.10K | 24.88K | 0.00 | 189.79K | 0.00 | 83.44K | 200.00K | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 95.82K | 198.83K | 190.58K | 144.51K | 150.39K | 254.59K | 501.37K | 571.42K | 500.18K | 404.18K | 200.22K | 176.54K | 223.46K | 333.75K | 408.35K | 1.81M | 1.22M | 1.29M | 856.01K | 757.78K | 796.83K | 423.12K | 392.50K | 552.96K | 1.12M | 896.52K | 652.62K | -500.00K | -600.00K | -100.00K | -100.00K |
| EBITDA | -13.88M | -11.51M | -10.64M | -10.82M | -10.85M | -13.14M | -6.87M | -21.31M | -31.52M | -38.03M | -27.79M | -24.86M | -49.10M | -35.85M | -2.48M | -2.40M | -2.83M | -2.97M | -1.14M | -853.34K | -2.22M | 955.59K | 1.67M | -4.03M | -27.20M | -26.37M | -22.97M | -11.80M | -12.10M | -8.40M | -3.10M |
| EBITDA Ratio | -21,134.32% | -2,337.93% | -1,170.60% | -41,184.60% | -1,722.58% | -541.05% | -20.54% | -114.85% | -448.72% | -3,399.73% | -35,547.39% | -3,998.82% | 345.15% | 341.96% | -27.82% | -482.39% | -36.85% | -37.03% | 1.57% | -12.95% | -45.50% | 20.93% | 17.16% | -46.74% | -469.25% | -551.70% | -1,960.93% | -1,180.00% | -1,344.44% | -8,400.00% | -3,100.00% |
| Operating Income | -14.05M | -12.06M | -10.71M | -10.96M | -10.85M | -13.88M | -2.22M | -18.55M | -27.63M | -38.44M | -27.99M | -24.10M | -6.31M | -1.82M | -3.04M | -1.76M | -3.46M | -3.64M | -2.00M | -1.61M | -2.99M | -352.21K | 1.29M | -4.58M | -28.47M | -27.26M | -23.34M | -11.40M | -11.80M | -8.20M | -3.00M |
| Operating Income Ratio | -21,402.08% | -2,269.07% | -1,170.60% | -41,184.60% | -3,363.29% | -766.50% | -10.12% | -140.01% | -440.38% | -3,399.73% | -35,547.39% | -4,032.67% | -58.98% | -19.17% | -38.57% | -24.74% | -57.19% | -61.56% | -33.58% | -24.75% | -60.82% | -4.64% | 13.25% | -48.50% | -488.08% | -531.69% | -1,993.02% | -1,140.00% | -1,311.11% | -8,200.00% | -3,000.00% |
| Total Other Income/Expenses | -1.13M | 345.52K | -10.51K | 17.68K | -5.32M | -3.91M | 2.77M | -10.32M | -13.14M | -4.26M | -1.17M | -943.16K | -37.20M | 1.82M | -2.12M | -3.33M | -1.28M | -1.28M | -1.24M | -10.38K | 28.48K | 369.77K | 371.83K | 386.58K | 26.50K | 1.92M | 276.87K | 900.00K | 900.00K | 300.00K | 200.00K |
| Income Before Tax | -15.18M | -11.71M | -10.72M | -10.94M | -16.17M | -17.79M | -14.31M | -28.76M | -35.73M | -42.70M | -29.16M | -25.05M | -49.96B | -39.61B | -5.17B | -5.09B | -4.74B | -4.93B | -3.24M | -1.62M | -2.96M | 17.57K | 1.66M | -4.19M | -28.44M | -25.34M | -23.07M | -10.50M | -10.90M | -7.90M | -2.80M |
| Income Before Tax Ratio | -23,117.58% | -2,204.06% | -1,171.75% | -41,118.20% | -5,013.18% | -982.62% | -65.13% | -217.05% | -569.36% | -3,776.61% | -37,030.66% | -4,190.46% | -466,936.68% | -416,112.49% | -65,509.12% | -71,415.40% | -78,353.34% | -83,266.70% | -54.36% | -24.91% | -60.24% | 0.23% | 17.08% | -44.41% | -487.63% | -494.19% | -1,969.38% | -1,050.00% | -1,211.11% | -7,900.00% | -2,800.00% |
| Income Tax Expense | 0.00 | 16.04K | -81.74K | 707.00 | 2.75K | -4.06M | -648.00K | -436.05K | 2.68M | 2.37M | 43.33M | -7.88M | 43.65M | 37.45M | 2.12M | -32.20M | 1.28M | 1.28M | 1.54M | 187.87K | -726.00 | 2.62K | -194.07K | -407.40K | -435.54K | -4.02M | -2.37M | 400.00K | 200.00K | 0.00 | -200.00K |
| Net Income | -15.18M | -11.73M | -10.64M | -10.95M | -16.13M | 74.95M | -14.31M | -27.56M | -35.73M | -42.70M | -29.16M | 5.61M | -49.96M | -39.61M | -5.17M | -5.09M | -4.74M | -4.93M | -3.54M | -1.80M | -2.96M | 14.95K | 1.84M | -4.17M | -28.03M | -23.25M | -20.97M | -10.80M | -10.80M | -8.00M | -2.60M |
| Net Income Ratio | -23,117.58% | -2,207.08% | -1,162.82% | -41,120.85% | -5,000.12% | 4,139.67% | -65.13% | -208.03% | -569.36% | -3,776.61% | -37,030.66% | 939.05% | -466.94% | -416.11% | -65.51% | -71.42% | -78.35% | -83.27% | -59.49% | -27.63% | -60.23% | 0.20% | 18.95% | -44.19% | -480.61% | -453.33% | -1,790.42% | -1,080.00% | -1,200.00% | -8,000.00% | -2,600.00% |
| EPS | -0.59 | -0.40 | -0.45 | -0.76 | -1.89 | 9.40 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.45 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| EPS Diluted | -0.56 | -0.40 | -0.45 | -0.76 | -1.89 | 9.00 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.31 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| Weighted Avg Shares Out | 29.34M | 29.34M | 23.90M | 14.39M | 8.53M | 8.08M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.29M | 1.29M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
| Weighted Avg Shares Out (Dil) | 30.90M | 29.34M | 23.90M | 14.39M | 8.53M | 8.30M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.30M | 1.32M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Tilmanocept as a novel tracer for lymphatic mapping...
Navidea Biopharmaceuticals Reminds Investors of Today's Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today issued a reminder to shareholders that the record date of its proposed rights offering is...
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Increased Macrophage Specific Arterial Inflammation Relates Uniquely to...
Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided an informational update to stockholders regarding its proposed rights offering and the expected key...
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on July 1, 2022, its largest shareholder and Vice Chair of the Board...
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “TAM Targeted Imaging Agents Binding CD206 and Selective Blocking...
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “CD206 Targeted Delivery of Bisphosphonate Payloads Alter Human Macrophage...
Navidea Biopharmaceuticals, Inc. (NAVB) Management on Q1 2022 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Operator Welcome to...
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended March 31, 2022....
Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Thursday, May 12, 2022 at...
Source: https://incomestatements.info
Category: Stock Reports